Medytox Posts Q3 Sales of 61 Billion Won and Operating Profit of 8.9 Billion Won

Sales Up 13% Year-on-Year

On November 10, Medytox, a biopharmaceutical company, announced through a provisional earnings disclosure that its consolidated sales for the third quarter reached 61 billion won. This represents a 13.3% increase compared to the same period last year.

The company has surpassed 60 billion won in sales for three consecutive quarters for the first time in its history, and expects to achieve record annual sales for the third consecutive year. Operating profit and net profit were 8.9 billion won and 7.2 billion won, respectively, marking increases of 48.3% and 90.5% compared to the same period last year.

The company's main business, the botulinum toxin product segment, drove strong results with a robust 38% year-on-year growth. Additionally, the rapid global expansion of 'Newlux,' a next-generation botulinum toxin product developed by its affiliate NewMeco, played a significant role. 'Newlux' is continuously expanding its registrations in Asia, Europe, and South America, and the hyaluronic acid filler 'Neuramis' is also expected to sustain sales growth through aggressive marketing. In particular, the company anticipates an even greater increase in sales once the next-generation fat-dissolving injection 'Newviju' and its proprietary fat-reducing probiotics are officially launched in the first half of next year.

A Medytox representative stated, "Botulinum toxin sales have shown balanced growth both domestically and internationally, underpinning our solid performance. We will further secure growth momentum with the fat-dissolving injection 'Newviju' and the fat-reducing probiotic health functional food 'MT961,' which is scheduled for release next year." The representative added, "We will also make every effort to obtain U.S. approval for our core project, the non-animal liquid-type botulinum toxin product 'MT10109L.'"

This content was produced with the assistance of AI translation services.